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SUMMARY
The dominant approach to decision-making in public health policy for infectious diseases relies 
heavily on expert opinion, which often applies empirical evidence to policy questions in a manner 
that is neither systematic nor transparent. Although systematic reviews are frequently 
commissioned to inform specific components of policy (such as efficacy), the same process is 
rarely applied to the full decision-making process. Mathematical models provide a mechanism 
through which empirical evidence can be methodically and transparently integrated to address 
such questions. However, such models are often considered difficult to interpret. In addition, 
models provide estimates that need to be iteratively reevaluated as new data or considerations 
arise. Using the case study of a novel diagnostic for tuberculosis, a framework for improved 
collaboration between public health decision-makers and mathematical modellers that could lead 
to more transparent and evidence-driven policy decisions for infectious diseases in the future is 
proposed. The framework proposes that policymakers should establish long-term collaborations 
with modellers to address key questions, and that modellers should strive to provide clear 
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explanations of the uncertainty of model structure and outputs. Doing so will improve the 
applicability of models and clarify their limitations when used to inform real-world public health 
policy decisions.
Keywords
Models; theoretical; Public health practice; Tuberculosis
1. Introduction
Public health policy decisions must balance a range of scientific, budgetary, social, and 
political considerations. Ideally, each of these elements should be considered in a transparent 
fashion before reaching a decision or implementing a specific policy. While socio-political 
considerations will always be somewhat subjective, scientific evidence can – in theory – be 
used to evaluate the potential epidemiological or economic impact of alternative decisions. 
For example, in the setting of a high-profile outbreak, the probability of making political 
gains or alleviating public fears is not objectively quantifiable (despite their importance to 
the decision-making process), but scientific outcomes, such as potential trajectories of the 
outbreak under different policy decisions, can be estimated quantitatively with appropriate 
tools using the best available data as inputs, such as the known incubation period.
In the realm of infectious diseases, the tools for integrating and translating scientific data 
into policy-relevant outcomes are often classified in the domain of ‘mathematical models’,1,2 
which are defined here as quantitative frameworks for the analysis of dependent happenings 
(events where the number affected at one time depends on the number already affected3). 
For example, systems of diagnosis and treatment are represented in mathematical terms such 
as the rate of movement from an infectious to a treated state. These models have the ability 
to translate existing scientific evidence into projected outcomes at the population level for 
both endemic diseases like tuberculosis (TB) and epidemic situations such as the Ebola virus 
disease (EVD) outbreak in West Africa in 2014–2015,4,5 in a way that is transparent and 
verifiable or refutable by external observers. These estimates can also help with clinical 
decision-making at the individual level, to improve patient outcomes.
Unfortunately for most public health decisions regarding the control of infectious diseases, 
such models are seldom constructed – and when they are, they often have limited impact 
upon the decision-making process. This is likely due to several factors, including 
perceptions that models are too complex to understand or too dependent on assumptions, 
coupled with a history of insufficient communication between public health practitioners 
with specific policy questions and modellers with the quantitative tools to address them.
Here, the potential role of mathematical modelling in decision-making for health policy in 
the realm of infectious diseases is explored, and key reasons why mathematical models have 
historically not fulfilled this potential are evaluated. To do this, the current status of 
modelling in public health decision-making is first outlined and a case study modelling 
question described. Details of how to construct a relevant model and how to link it to policy 
are then given, and some of the potential limitations and challenges of using modelling 
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described. Finally, a framework by which improved collaborations between public health 
stakeholders and modellers may broadly benefit public health is proposed.
2. Current role and potential opportunities for modelling in public health 
decision-making
The use of structured frameworks for applying evidence to public health decision-making is 
well established.6 For example, the World Health Organization (WHO) advocates the use of 
the GRADE process,7 which is a framework that connects a public health question to an 
evidence-based analysis and recommendation.8 The United States Preventive Services Task 
Force (USPSTF) similarly uses decision-making algorithms to assess the level and quality of 
evidence to support the introduction of specific interventions.9 However, these frameworks 
for using scientific evidence to support policy decisions often lack quantitative assessments 
of how different decisions will impact health at a population level.
This is especially true in the realm of infectious diseases, where dynamics of transmission 
may cause great disparity between the individual-level benefit or harm of an intervention 
(for example, side effects of a vaccine for a rare disease such as polio that may outweigh an 
individual’s risk of contracting the disease) and its population-level impact (for example, 
maintaining elimination of polio through herd immunity). As a result, in settings where 
population-level benefits are unproven, interventions with strong scientific evidence for 
individual effectiveness may be recommended over those with a potentially dramatic impact 
for populations. This decision-making process, if uninformed by insight at the population or 
system level (as provided by models), may perversely result in outcomes that are good for 
certain people, but bad for the population as a whole.
Models can address this knowledge gap by estimating the effects of interventions when the 
collection of population-level empirical evidence (e.g., from cluster-randomized trials) is 
infeasible, unethical, or untimely. For example, mathematical models suggested that 
universal voluntary HIV testing and immediate antiretroviral therapy (ART) might 
dramatically reduce future HIV transmission,10–12 even though the individual-level 
effectiveness of ART at higher CD4+ T-cell counts is small,13 and reduced transmission at 
the population level is difficult to prove empirically. By projecting population-level effects 
of potential interventions, the models informed not only key policy decisions but also the 
design of future clinical trials.14
Despite the potential impact that model outputs can have on public policy decisions, the use 
of models by public health decision-makers has traditionally been limited.2 Many public 
health and policy decisions must be reached rapidly, in too short a time for new models to be 
developed, parameterized, and calibrated. Modellers must therefore achieve a balance 
between anticipating future policy questions (in which case models may ultimately not 
speak to the specific policy question at hand) and responding to existing questions (in which 
case models may be constructed too late to inform policy decisions). In addition, as 
mentioned above, complex models that are poorly presented are unlikely to be used by time-
pressured policymakers. Furthermore, it remains unclear in most settings how to weigh 
evidence from models against other epidemiological and clinical data. As described below, 
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all models must make certain assumptions and manage attendant uncertainty. These aspects 
of models are often not well-understood by public health stakeholders, and as a result, model 
outputs may be seen as difficult to interpret and untrustworthy. A framework by which 
modellers and decision-makers can work together to more appropriately incorporate 
evidence from infectious disease models into public health decisions, without over- or 
underemphasizing the importance of those models, is proposed here.
3. Modelling infectious diseases for policy: the example of a rapid TB 
diagnostic
To demonstrate the utility and process by which mathematical models can inform infectious 
disease policy, the case study of a new molecular diagnostic test for TB is used: the Xpert 
MTB/RIF test (Xpert).15 Xpert provides a comparatively rapid, point-of-treatment diagnosis 
in under two hours, if placed in settings where individuals present for initial TB diagnosis 
and/or follow-up evaluation. Xpert is also substantially more sensitive than the most widely 
used diagnostic test for TB worldwide (sputum smear microscopy). However, at over 10 
times the cost of sputum smear microscopy (which costs less than $2 fully-loaded per test, 
compared to about $20 for Xpert), scale-up of Xpert has the potential to dramatically 
increase the cost of TB control in high-burden settings.
The key policy-related questions around the use of Xpert are the following: Do the clear 
individual-level benefits of improved diagnosis translate into population-level effects on 
transmission, and if so, would scale-up of Xpert have sufficient impact to justify the added 
cost (i.e., would Xpert be cost-effective)? These questions can be, and have been, addressed 
effectively using mathematical modelling.
In the case of Xpert, an initial modelling study projected the impact on TB-associated 
morbidity and mortality in six countries of southern Africa.16–18 This study adopted a 
regional approach, which allowed the authors to use a single model framework (due to 
similar epidemics across the six countries) and existing data (which are reported on the 
national level). A global model would likely have required more model complexity, whereas 
a sub-national model might have been limited by available data or generalizability. The 
authors aimed primarily to publish their results in the scientific literature, although the 
model has subsequently been used in country-level discussions and extended to other 
regions. The model predicted a relatively large potential population level impact of Xpert on 
TB transmission and mortality, based on the assumption that increased rapid diagnosis 
would increase treatment rates. In the absence of pre-existing data, this model had to make a 
number of reasonable simplifying assumptions, including the proportion of individuals with 
TB who would ultimately be diagnosed by the existing algorithm in the absence of Xpert 
and the speed at which that diagnosis might happen. These results – which reflected the best 
available data and assumptions at the time – were used to support policy recommendations 
to scale up Xpert in the region and worldwide.
Subsequent clinical trials revealed that Xpert did not identify many more patients than were 
already being started on treatment, due to unexpectedly high levels of empiric treatment 
practices in TB-endemic settings.19,20 Using this new information, the model was then 
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revised to account for empiric treatment practices, and new estimates predicted a much 
smaller impact of Xpert.19 Several of these models were extended into cost-effectiveness 
analyses of Xpert scale-up.18,21
This case study illustrates the ability of models to iteratively incorporate updated data, 
leading to better estimates and highlighting existing weaknesses in both model assumptions 
and available data over time. A pertinent translation of individual-level effect to population 
impact is also displayed. Unfortunately, the case study also demonstrates the challenges in 
linking model results to policy. Major obstacles exist to the implementation of Xpert, 
especially in trying to use Xpert as a true point-of-care test.22 Nevertheless, despite its 
impact on population health being initially relatively uncertain, Xpert has received strong 
support from policymaking bodies such as the WHO,23 based primarily on systematic 
reviews of sensitivity and specificity. This recommendation places pressure on many high-
burden countries to scale Xpert up,24 and at tremendous expense. Even in light of emerging 
data and updated model projections that suggest Xpert may not improve population-level 
outcomes,19 recommendations to implement Xpert have become increasingly strong, 
partially due to political momentum and the known individual-level benefits of Xpert.
The policy–modelling disconnect in recommendations for Xpert contrasts, for example, with 
that for systematic screening for TB in high-risk populations. Systematic screening for TB 
has been shown in multiple mathematical models to have a potentially dramatic impact at 
the population level,25–28 but the benefits of systematic screening at the individual level are 
difficult to prove.29 The recommendation for systematic screening is therefore much less 
enthusiastic.30 As a result of this discrepancy between individual-level evidence (which is 
easier to collect directly but arguably less important to public health) and population-level 
evidence (which is difficult to collect directly and thus often requires models but is critical to 
public health decision-making), many countries are pressured to implement Xpert rather 
than systematic screening. This pressure exists despite the evidence from models that 
systematic screening might have much greater impact on reducing TB at the population level 
– and potentially at a more favourable cost–effectiveness ratio.26
In summary, as shown by the case study of Xpert, modelling interventions is often the only 
way to evaluate the comparative effectiveness (and cost-effectiveness) of interventions at the 
population level in the short term. In doing so, models may not only help to prioritize those 
interventions that might have greatest impact at the population level, but may also identify 
the data elements needed to better inform estimates of such impact for different public health 
policies.21 This process – which ideally occurs iteratively as new data emerge – can lead to 
better alignment between research efforts and policy priorities. However, major obstacles 
exist to the implementation of this process, and current practice continues to prioritize 
infectious disease interventions with more benefit for individuals than for populations.
4. Building useful models
Developing a useful model includes identifying, in sequence (1) a useful question and its 
epidemiological context, (2) a framework through which that question could be addressed, 
(3) the parameters required to address the specified question using that framework, and (4) 
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the empirical evidence available to inform meaningful values of those parameters (for 
examples and further details see publications by Vynnycky and White31 and Keeling and 
Rohani32). Once a question, framework, parameters, and empirical evidence have been 
identified, the model can then be used to inform decision-making by projecting the potential 
outcomes associated with different policy decisions. For example, in the Xpert case study, 
the question of interest was how big would the impact of this new diagnostic test be? The 
epidemiological setting was six countries with high TB incidence.18 The framework utilized 
was a transmission model that used both natural history and TB control parameters, such as 
treatment success, informed by country-level TB programme data.
For models to be useful to decision-makers, they must be both relevant and 
methodologically sound. In general, useful models are built to answer a key question that 
should guide the structure and complexity of the model (rather than the model determining 
the question). One such question might be to evaluate the expected epidemiological and 
economic impact of different strategies for scaling up Xpert for TB diagnosis (e.g., 
centralized or in individual clinics), or the required bed capacity during the recent EVD 
outbreak.33 Defining a central question also helps to inform the structure of the model, 
which should incorporate relevant scientific data (e.g., transmission rates, existing levels of 
infection control and treatment). The epidemiological setting is also important; for example, 
a model of implementing Xpert should include not only the sensitivity and specificity of the 
test but also the diagnostic processes, underlying disease prevalence, and clinical algorithms 
in the chosen setting. A model of TB diagnosis in the USA would need to account for 
immigration, for instance, whereas a model of TB in Sub-Saharan Africa would require a 
more detailed description of ART scale-up.18 In some cases, the same model structure can 
be modified to explore ‘first-pass’ results across a range of settings and interventions;34 in 
other cases (or when more precisely calibrated results are needed), separate models will be 
required for each setting.
In general, models allow for an exploration of the system and give a holistic picture of the 
realm of possible outcomes. As such, uncertainty and sensitivity analyses around the main 
components of the model are critical. Uncertainty analysis translates uncertainty in model 
‘inputs’, such as the proportion of patients accessing different diagnostic services, into 
uncertainty in model ‘outputs’, such as the impact of a new diagnostic on mortality. 
Sensitivity analyses aim to attribute portions of this uncertainty to specific parameters. In a 
one-way sensitivity analysis, for example, a key parameter (such as the TB transmission 
rate) might be set sequentially to its highest or lowest plausible values, and the model results 
assessed at each of those points. In the case of Xpert, population-level impact has been 
shown to be very sensitive to existing levels of empirical therapy for TB.16,17 Broader 
consideration of model uncertainty would explore the impact of a range of plausible 
empirical treatment levels as well as other model parameters (for example, transmission 
rates) or indeed do a more comprehensive sampling over all parameters.35
Ultimately, the estimates of any model can only be as accurate as their supporting data, but 
models can also describe that uncertainty to decision-makers, allowing them to make the 
most appropriate decisions given existing, imperfect evidence. As such, modelling results 
with wide confidence intervals that reflect this uncertainty are often valuable to 
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policymakers, as they demonstrate the current state of knowledge.36 The alternative, where 
false confidence in predictions is gained via modelling based on strong unsupported 
assumptions, must be avoided despite the temptation of the ‘clarity’ of results that such 
assumptions can provide.
5. Linking model results to public health policy around infectious diseases
Models can inform infectious disease public health policy in at least three ways (see Figure 
1). Firstly, models can systematically use epidemiological data to better understand the 
larger systems in which policy decisions must be made. For example, mathematical models 
of Xpert scale-up in Africa have suggested that baseline diagnostic patterns affect the 
incremental benefit of a novel, more sensitive test,17 thereby suggesting that policymakers 
should target Xpert roll-out to areas with the weakest existing diagnostic systems.
Secondly, as described above in the case of universal HIV testing and treatment, models can 
apply a transparent framework to compare the potential population-level impact of 
interventions in situations where collecting empirical evidence might be logistically, 
monetarily, or ethically infeasible.37,38 Even when broader empirical studies are feasible, 
interim policies must nonetheless be set; models can help these policies make maximum use 
of existing evidence before definitive results are known.
For example, modelling estimates for the recent EVD outbreak in West Africa published in 
September 2014 predicted that without interventions, Liberia and Sierra Leone would have 
approximately 550 000 reported Ebola cases by January 2015.47 The predictions over a 
shorter timeframe were closer to what actually occurred; for estimates of case numbers by 
September 2014, the model overestimated the number of cases by only 8.8% in Liberia, and 
underestimated the number of cases by 7.6% in Sierra Leone. The later projections to 
January 2015 were substantially less accurate. These results, however, demonstrated at the 
time what most needed to be done to control the outbreak. Thus this is an example of where 
modelling results may appear ‘wrong’ but can still be useful. Furthermore, the results made 
under the assumption of no intervention highlight the impact that outbreak control 
interventions had on the magnitude of the outbreak – and these could later be compared to 
an alternative model structure that incorporates those interventions to further evaluate the 
impact of those measures. By highlighting how serious things could be if nothing was done, 
models emphasized the need for control interventions and the aspects of those interventions 
that might be most important from an epidemic control perspective.
Thirdly, modelling can point to data gaps that, if filled, could better assist decision-making 
and control of infectious diseases in the future. For example, TB models might find that the 
comparative impact of Xpert scale-up strategies depends strongly on the amount of ongoing 
TB transmission in a community, which in many places may not be known.6 These results 
could motivate further data-gathering activities (e.g., molecular epidemiological 
characterization of acommunity,39,40 or synthesis of existing programmatic data on TB 
incidence41) that could help to improve decision-making related to Xpert scale-up in the 
future. For the spread of rubella, modelling has already led to the collection of new missing 
data.42
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In each of these cases, mathematical models provide public health decision-makers with key 
pieces of knowledge that can inform evidence-based decision-making. Furthermore, unlike 
expert opinion (which often holds sway purely on the basis of reputation or existing dogma), 
models accomplish this task in a way that is quantitative and open to questioning (or 
modification) by others in the field. When a model’s structure, methods, assumptions, and 
parameters are laid out in a reproducible manner with direct communication and guidance to 
those with less methodological expertise, their results should be transparent and accessible 
rather than being perceived as a ‘black box’ that is susceptible to manipulation and is too 
difficult to understand.
6. The challenges of using models and approaches to addressing them
These potential benefits of infectious disease models can be offset by excess complexity.37 
While in theory, models are fully transparent, many models are made so complex that few 
outside the modelling community can fully understand their mechanics. In addition, while 
models should be tailored to answer a specific policy question of interest, they are often 
presented in such a fashion that does not speak readily to key policy decisions.37 Modellers 
must strive to produce transparent outputs that can directly inform the policymaking process, 
even when this requires some simplification to be made.
An important way to improve transparency is to publish the raw data as well as any 
modelling code.43 Whether provided in the appendix of the publication or in online format, 
this would provide readers with access to the model and the ability to closely review its 
methods, thus making a more informed determination as to whether the assumptions and 
data used were sufficient. Open data and code would also allow for the model to be 
improved and developed iteratively by others in the modelling community to answer other 
policy-relevant questions.
In addition, care must be taken when broadly applying a model specifically structured to 
answer a certain question. For example, a modelling evaluation of Xpert scale-up across 
southern Africa18 is unlikely to provide useful guidance on where to place Xpert machines 
in the USA,44 or whether to supplant other funds to pay for Xpert testing.45,46
However, models can be, and often are, reconstructed as new evidence or considerations 
come to light. The development begins with models that provide initial insight; such initial 
models are gradually replaced by more complete models that incorporate updated 
information. This process of iteratively evaluating modelling output provides a framework in 
which to place new evidence and improves our understanding of both the problem and the 
utility of the modelling tool being applied. While the need for such iteration can be seen as a 
problem with the initial model or input data, it is more appropriately seen as reflecting the 
natural course of scientific inquiry, in which better data and better tools to utilize those data 
are continually being developed.
Presenting the uncertainty around modelling results, as described above, presents a further 
challenge as it often reflects limited available data on key parameters. In such cases, 
modellers should honestly portray this uncertainty rather than providing results that appear 
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more reliable, and policymakers should make decisions based on this uncertainty rather than 
requesting results that are more precise. Not including such uncertainty may be justified in 
specific cases47 – such as when the infectious disease situation being modelled (e.g., when 
considering just a ‘no intervention’ scenario) is unrealistic and specific policy decisions are 
not based on this quantitative value – but is generally not recommended.
There are also significant ethical considerations that must be taken into account when using 
the results of mathematical models to design public health interventions. These include 
considering the values and preferences of the target population as well as the available 
resources.48 Determinants of health behaviour must be viewed in a social context, including 
the cultural beliefs, historical patterns, and choices available to the local population. If 
applied in a vacuum, modeling results may not be relevant to the target population and the 
estimated impact of a chosen intervention will likely not be realized.
7. Recommendations for a future framework
How can we improve the utility of modelling for infectious disease relevant to public health 
decision-making in the future? One important component of any such strategy should 
involve ongoing collaboration and interaction between infectious disease modellers and 
public health stakeholders. Such communication and collaboration enables decision-makers 
to appropriately understand the complexity of model structure and uncertainty in modelling 
results, and modellers to inform additional refinements or data-gathering efforts to reduce 
that complexity and uncertainty. In addition, both modellers and public health policymakers 
must view the results of models within the social context of the target population to consider 
the ethical impact of applying modelling results to specific settings. Fostering such 
collaboration will improve the availability of models to public health practitioners, as well as 
the quality of model structure and relevance of results. It will also improve the likelihood 
that the perspectives and needs of all critical stakeholders are included.
To promote such public health stakeholder collaboration and optimize the role mathematical 
modelling can have in public health decision-making in the field of infectious diseases, an 
iterative process for model development is recommended (Figure 2). The key stages in this 
process are: (1) Policymakers engage modellers early in the decision-making process and 
inform them of the key public health questions that are being considered in a given 
population and/or clinical setting. (2) Modellers use this information to construct models 
that are most likely to effectively address these questions. (3) Modellers strive to reduce, or 
fully justify, the complexity of their models and explain the context and uncertainty of their 
outputs to decision-makers and others who could openly interrogate their methods. (4) 
Decision-makers seek to incorporate model results into their decision-making process 
(including decisions for more data gathering) and inform modellers of where model 
structures, outputs, and uncertainty could be refined for future decision-making.
To succeed in this endeavour, it is important that modellers and decision-makers build 
mutual trust over time; these steps are difficult to complete in a ‘one-off’ fashion for each 
new question that arises. Platforms for such interaction, such as conferences and workshops, 
should be developed and promoted to stimulate discussion and interaction around the 
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important questions and how to address them, including how to share key data. As effective 
communication is only possible when modellers and stakeholders speak the same 
‘language’, it is critical that these communities work together to establish long-term 
collaborative relationships.
As an example of such longer-term collaboration between infectious disease modellers and 
infectious disease policymakers, the TB public health community has established platforms 
where engaged stakeholders can interact. For example, the TB Modelling and Analysis 
Consortium (TB MAC) brings together quantitative researchers, policymakers, TB 
programmes, and donors to identify TB control questions that require modelling input.49 
Discussion and interaction between TB control stakeholders is also supported by the TB 
Modelling group at Johns Hopkins,50 which holds frequent international conference calls to 
examine the latest research and areas of interest. Such multidisciplinary collaboration is also 
being seen in other infectious disease fields, where modelling studies have been used to 
assist public health interventions and policy-making decisions around HIV, influenza, and 
EVD.12,51–53 While such relationships take time to build, are difficult to incentivize from 
both the academic and public health perspectives, and may not yield immediate results, 
increased communication between modellers and public health policymakers is arguably the 
only viable path towards bringing the wealth of existing epidemiological evidence to bear in 
making public health decisions for infectious diseases.
8. Conclusions
Infectious disease modelling can provide important and useful data to inform public health 
policy by improving our knowledge of epidemic disease spread, comparing the impact of 
potential public health interventions and understanding gaps in existing data used to inform 
public health decision-making. For models to be most useful, challenges in applying 
modelling results to public health practice, including the complexity of model structure and 
uncertainty of model outputs and their relevance to important policy questions, must be 
understood and considered. While modelling will not provide all the answers for public 
policy, it can provide useful quantitative evidence when large clinical studies are not 
possible or are still underway. A framework that can be used to improve the process of 
applying modelling to public health decision-making for infectious diseases is proposed. 
Collaboration between public health stakeholders and modellers is essential to heighten the 
transparency and public health relevance of models, to optimize the use of epidemiological 
data for decision-making, and to develop policies that incorporate scientific evidence to 
improve the control of infectious diseases worldwide.
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Figure 1. 
Roles and challenges of infectious disease models for public health decision-making.
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Figure 2. 
Proposed framework for interaction between infectious disease modellers and public health 
practice. Stakeholders in public health practice should identify the key relevant public health 
questions for modellers to address and the existing data that can be used to inform model 
structure and parameters. Once shared and communicated with modellers, further discussion 
should pertain to the relevant model structures best suited to address the question and the 
required inputs. Subsequently, through ongoing communication, evidence gaps can be 
identified and modelling outputs can be reviewed and understood in the context of model 
uncertainty and generalizability. Once the model is refined and finalized, the outputs can be 
used to support data-informed decision-making. In this way, long-term collaboration 
between public health practitioners and mathematical modellers can ensure that models have 
optimal impact on evidence-based public health decision-making.
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